TWST Twist Bioscience Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Synthetic DNA production and related biotechnological research and manufacturing
• • Strategic real estate expansion: Lease amendment adds 33,000 sq. ft. for R&D, manufacturing, and administration in South San Francisco
• • Lease extended to June 30, 2036 with $119.2M total rent obligations including 3% annual rent escalations
• • $24.4M tenant improvement allowance from landlord to support facility upgrades
• • Option to expand by another 33,000 sq. ft. by December 31, 2026 on fourth floor

Risk Factors

• • Regulatory risk: dependency on ISO 27001:2022 cybersecurity certification for information security management systems impacting operations and data protection
• • Geopolitical/macroeconomic risk: exposure to cyberattacks by nation-state actors risking technology theft and operational disruption
• • Operational vulnerability: reliance on single-source supplier for critical DNA synthesis component risking production delays
• • Competitive risk: rivalry with Thermo Fisher Scientific, Illumina, and others who may develop silicon chip synthetic DNA technologies threatening market position
• • Financial risk: accumulated deficit $1,319.6M and net losses $204.6M-$208.7M in prior years raising sustainability concerns

Management Discussion & Analysis

• • Revenue $376.6M, up 20% YoY from $313.0M, driven by NGS tools +$39.0M and synthetic genes +$20.9M
• • Gross margin 50.7% vs 42.6%, up 8.1% due to revenue growth and flat fixed manufacturing costs
• • Best segment: NGS tools $208.1M (55% of revenue), worst: DNA libraries $11.2M (3% of revenue)
• • Net cash used in operating activities $47.6M vs $64.1M; capital expenditures $28.0M; financing cash inflow $28.5M including $15.0M from royalty sale
• • Management expects current cash, investments and operations to fund >12 months but may raise financing if needed; significant lease expansion signed through 2036

What are the latest TWST SEC filings in 2026?

Twist Bioscience Corp (TWST) has filed a 10-K annual report on November 17, 2025, a 10-Q quarterly report on May 4, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TWST file its most recent 10-K annual report?

Twist Bioscience Corp (TWST) filed its most recent 10-K annual report on November 17, 2025. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TWST 10-Q quarterly reports?

Twist Bioscience Corp (TWST)'s most recent 10-Q quarterly report was filed on May 4, 2026. SignalX displays every TWST 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TWST filed recently?

Twist Bioscience Corp (TWST)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TWST insider trading activity (Form 4)?

SignalX aggregates every TWST Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TWST file with the SEC?

Twist Bioscience Corp (TWST) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TWST filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Twist Bioscience Corp (TWST).

What is TWST's SEC CIK number?

Twist Bioscience Corp (TWST)'s SEC CIK (Central Index Key) number is 1581280. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1581280 to look up all TWST filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TWST return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Twist Bioscience Corp (TWST) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.